Compositions and methods for regulating glucose homeostasis and insulin action

Patent metadata

Field	Value
Publication number	US-9492448-B2
Application number	US-201314409793-A
Country	US
Kind code	B2
Filing date	Jun 20, 2013
Priority date	Jun 20, 2012
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.

First claim

What is claimed is:

1. A method for treating ischemia reperfusion injury wherein said method comprises administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier, optionally at least one additional therapeutic agent, and an effective amount of at least one compound selected from the group consisting of:

thereby treating ischemia reperfusion injury.

2. The method of claim 1 , wherein said compound is a mitochondrial uncoupler.

3. The method of claim 1 , wherein said ischemia reperfusion injury is kidney ischemia reperfusion injury, brain ischemia reperfusion injury, or cardiac ischemia reperfusion injury.

4. The method of claim 1 , wherein said method reduces reperfusion-induced mitochondrial oxidative stress and mitochondrial fragmentation.

5. The method of claim 1 , wherein said compound is administered at a dosage ranging from about 0.1 mg/kg to about 50 mg/kg body weight.

6. The method of claim 5 , wherein said compound is administered at a dosage ranging from about 0.5 mg/kg to about 25 mg/kg body weight.

7. The method of claim 6 , wherein said compound is administered at a dosage ranging from about 1.0 mg/kg to about 5.0 mg/kg body weight.

8. The method of claim 5 , wherein said compound is administered as a unit dose ranging from about 10 mg to about 500 mg.

9. The method of claim 1 , wherein said compound is administered more than once.

10. The method of claim 1 , wherein said compound is a mitochondrial protonophore uncoupler lacking protonophore activity at the plasma membrane.

11. The method of claim 10 , wherein said compound is BAM15:

12. The method of claim 1 , wherein said compound increases oxygen consumption.

13. The method of claim 1 , wherein said compound reduces cellular reactive oxygen species.

14. The method of claim 1 , wherein said compound depolarizes the mitochondrial inner membrane.

15. The method of claim 1 , wherein said compound increases oxygen consumption rate without donating electrons to the electron transport chain.

Assignees

• Univ Virginia Patent Foundation

Inventors

• Hoehn Kyle
• Kenwood Brandon

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title